Magical Trade
Sunday, May 22, 2022
  • Home
  • Trade News
  • Email Whitelisting
  • Privacy Policy
No Result
View All Result
  • Home
  • Trade News
  • Email Whitelisting
  • Privacy Policy
No Result
View All Result
Magical Trade
No Result
View All Result
Home Trade News

‘End of the war is in sight’ — Cramer says Dr. Gottlieb’s end-of-pandemic call bigger than jobs data

by
November 5, 2021
in Trade News
0
0
SHARES
0
VIEWS
Share on FacebookShare on Twitter

RELATED POSTS

First baby formula shipment arrives from Europe on U.S. military plane

Conditions Are Ripe for a Deep Bear Market

CNBC’s Jim Cramer on Friday took comfort in a prediction by Dr. Scott Gottlieb that the pandemic phase of Covid could be over by January.

“Dr. Gottlieb basically said the war’s over, and that’s just incredible,” Cramer said. Gottlieb, who had served as FDA chief under former President Donald Trump, is currently a Pfizer board member.

“By Jan. 4, this pandemic may well be over, at least as it relates to the United States, after we get through this delta wave of infection,” Gottlieb said on “Squawk Box.” “We’ll be in a more endemic phase” after that.

Gottlieb referenced Jan. 4 because that’s the new deadline for the Biden administration’s mandate for larger U.S. companies to ensure their employees are fully vaccinated or regularly tested for Covid.

“The end of the war is in sight,” Cramer said.

Gottlieb’s comments made on CNBC earlier Friday morning were more important than the strong October jobs numbers, the “Mad Money” host said.

“They were talking about employment, I don’t even care about the employment numbers — the pandemic ended,” Cramer said. “It sounds like it’s over.”

“Today is a good day,” Cramer said, referring to Pfizer’s announcement that internal data showed its oral Covid pill — when administered with a widely used HIV drug — indicated an 89% reduction in the risk of hospitalization or death in adults who’ve been exposed to the coronavirus. Pfizer shares were up more than 8% on Friday morning.

“The only people who are unhappy are the people who own the stocks that required you to stay inside,” Cramer said. So-called economic reopening stocks advanced Friday morning while stay-at-home names came under pressure.

Merck‘s antiviral Covid pill, developed with Ridgeback Biotherapeutics, was shown to reduce the risk of hospitalization and death from Covid by 50%, according to internal data released early last month. Merck shares were down nearly 9% on Friday, with the company facing competition in treatments.

Unlike Pfizer, Merck does not have a Covid vaccine.

Disclosure: Scott Gottlieb is a CNBC contributor and is a member of the boards of Pfizer, genetic testing start-up Tempus, health-care tech company Aetion and biotech company Illumina. He also serves as co-chair of Norwegian Cruise Line Holdings? and Royal Caribbean’s “Healthy Sail Panel.”

ShareTweetPin

Related Posts

First baby formula shipment arrives from Europe on U.S. military plane

by
May 22, 2022
0

A military cargo plane carrying the first shipment of infant formula from Europe to address a critical shortage in the...

Conditions Are Ripe for a Deep Bear Market

by
May 22, 2022
0

Previous bear markets have bottomed out when the Federal Reserve eased monetary policy. Photo: JOSHUA ROBERTS/REUTERS With the S&P 500...

Quarterly Starts by Purpose and Design: "Built for rent" Increasing

by
May 22, 2022
0

by Calculated Risk on 5/22/2022 11:48:00 AM Along with the monthly housing starts for April last week, the Census Bureau...

SpaceX looks to raise $1.7 billion in new funding, boosting its valuation to $127 billion

by
May 22, 2022
0

A Falcon 9 rocket launches a batch of Starlink satellites to orbit on April 29, 2022. SpaceX SpaceX is raising...

Series I Savings Bonds: What Readers Want to Know

by
May 22, 2022
0

The initial annualized rate on new Series I savings bonds sold from May through October of this year is 9.62%....

Next Post

1st Look at Local Housing Markets in October

Buy Nokia Before It Dominates the 5G Space

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

email

Get the daily email about stock.

Please Enter Your Email Address:



By opting in you agree to our Privacy Policy. You also agree to receive emails from us and our affiliates. Remember that you can opt-out any time, we hate spam too!

MOST VIEWED

  • Fund manager believes FAANG is dead — says now it’s all about MANTA

    0 shares
    Share 0 Tweet 0
  • Forget Tesla — this auto stock is the one to buy right now, analyst says

    0 shares
    Share 0 Tweet 0
  • Bank of America names its top global tech stocks — including one it says has upside of 100%

    0 shares
    Share 0 Tweet 0
  • ‘Conviction sell’: UBS says avoid these global stocks amid rising headwinds

    0 shares
    Share 0 Tweet 0
  • These are the global stocks to own if stagflation hits, according to Credit Suisse

    0 shares
    Share 0 Tweet 0
  • Home
  • Trade News
  • Email Whitelisting
  • Privacy Policy
All rights reserved by www.magicaltrade.net
No Result
View All Result
  • Email Whitelisting
  • Home
  • Privacy Policy

All rights reserved by www.magicaltrade.net